MedTrace Logo

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

NCT06041529 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2026-02-13

No results posted yet for this study

Summary

This study is to compare the efficacy and safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination and Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients with Essential Hypertension Uncontrolled by Telmisartan and Amlodipine Combinations

Conditions

  • Essential Hypertension

Interventions

DRUG

Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg

PO, Once daily(QD), 8 weeks and 26 weeks if applicable

DRUG

Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg

PO, Once daily(QD), 8 weeks and 26 weeks if applicable

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Sanghyun Ihm · The Catholic University of Korea Bucheon St.Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-18
Primary Completion
2026-02-28
Completion
2026-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06041529 on ClinicalTrials.gov